S. Wasserman

发表

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk.

A. Hirayama, A. Kiyosue, N. Honarpour, 2016, The American journal of cardiology.

Cardiovascular drug development: is it dead or just hibernating?

D. DeMets, P. Libby, R. Califf, 2015, Journal of the American College of Cardiology.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

A. Keech, R. Giugliano, M. Sabatine, 2017, The New England journal of medicine.

Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implications

S. Wasserman, J. N. Topper, 2004, Vascular medicine.

Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.

B. Greenberg, P. Eisenberg, S. Wasserman, 2015, JACC. Heart failure.

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

J. Gibbs, M. Emery, M. Gibbs, 2016, Journal of clinical pharmacology.

Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study

R. Rosenson, E. Stroes, L. Cho, 2014, Cardiovascular Drugs and Therapy.

Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events.

J. Larosa, T. Pedersen, S. Wasserman, 2013, The American journal of cardiology.

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

A. Keech, R. Giugliano, M. Sabatine, 2019, Circulation.

Treatment of anemia with darbepoetin alfa in heart failure.

P. Ponikowski, W. Abraham, M. Klapholz, 2010, Congestive heart failure.

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.

Jennifer G. Robinson, N. Sattar, J. Robinson, 2016, The lancet. Diabetes & endocrinology.

Effect of evolocumab on cholesterol synthesis and absorption[S]

S. Wasserman, R. Scott, Ransi M. Somaratne, 2016, Journal of Lipid Research.

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia

P. Ponikowski, K. Dickstein, A. Cohen-Solal, 2006 .

Nattokinase—This is Big News for Heart & Circulatory Health

H. Watt, L. Desser, S. Wasserman, 2003 .

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole

F. Raal, E. Stein, S. Wasserman, 2012, Circulation.

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

R. Giugliano, M. Sabatine, M. Eriksson, 2014, Journal of the American College of Cardiology.

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

J. Gibbs, M. Emery, S. Wasserman, 2019, Clinical pharmacology in drug development.

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.

A. Keech, R. Giugliano, M. Sabatine, 2019, Journal of the American College of Cardiology.

HIV and Hepatitis C – Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 ( PCSK 9 ) : An Apparent “ PCSK 9 – Lipid Paradox ”

P. Ganz, C. Grunfeld, P. Kohli, 2016 .

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

P. Ganz, C. Grunfeld, P. Kohli, 2016, Journal of the American Heart Association.

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial

P. Thompson, C. Ballantyne, S. Nissen, 2016, Clinical cardiology.

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.

M. Sabatine, Z. Fayad, V. Mani, 2018, European heart journal.

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

F. Raal, D. Blom, E. Stein, 2015, The Lancet.

AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody in

R. Giugliano, M. Sabatine, N. Desai, 2014, Journal of the American College of Cardiology.

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

G. Watts, S. Wasserman, R. Scott, 2018, Arteriosclerosis, thrombosis, and vascular biology.

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.

G. Watts, F. Raal, R. Santos, 2017, The lancet. Diabetes & endocrinology.

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

F. Raal, E. Stein, N. Honarpour, 2013, Circulation.

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role[S]

R. Giugliano, M. Sabatine, N. Seidah, 2016, Journal of Lipid Research.

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.

R. Giugliano, M. Sabatine, F. Raal, 2019, Journal of the American College of Cardiology.

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

J. Gibbs, M. Emery, S. Wasserman, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial

A. Keech, R. Giugliano, M. Sabatine, 2018, JAMA cardiology.

Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia Heart Failure

P. Armstrong, H. Krum, B. Massie, 2008 .

Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance

D. Blom, S. Wasserman, R. Scott, 2015 .

Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.

D. Blom, S. Wasserman, R. Scott, 2015, Circulation research.

Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF)™ Trial

S. Solomon, M. Pfeffer, R. Diaz, 2006 .

AMG 145, A Monoclonal Antibody Against PCSK9, Significantly Reduces Lipoprotein (a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LAPLACE-TIMI 57 Trial

R. Giugliano, M. Sabatine, N. Desai, 2013 .

Abstract 17016: Trial Assessing Long-Term Use of PCSK9 Inhibition in Patients with Genetic LDL Disorders (TAUSSIG): Efficacy and Safety in Patients with Homozygous Familial Hypercholesterolemia Receiving Lipid Apheresis

F. Raal, E. Stein, E. Bruckert, 2014 .

Trial evaluating evolocumab, a pcsk9 antibody, in patients with homozygous fh (tesla): Results of the randomized, double-blind, placebo-controlled trial

F. Raal, D. Blom, E. Stein, 2014 .

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data

A. Keech, R. Giugliano, M. Sabatine, 2019, JAMA cardiology.

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab

R. Giugliano, M. Sabatine, N. Desai, 2017, JAMA cardiology.

Expression of the bumetanide-sensitive Na-K-Cl cotransporter BSC2 is differentially regulated by fluid mechanical and inflammatory cytokine stimuli in vascular endothelium.

M. Gimbrone, K. R. Anderson, S. Wasserman, 1997, The Journal of clinical investigation.

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolem

F. Raal, E. Stein, S. Wasserman, 2012 .

Pooled safety analysis of darbepoetin alfa in the treatment of symptomatic heart failure

P. Ponikowski, W. Abraham, J. Ghali, 2008 .

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals

R. Giugliano, M. Sabatine, J. Gibbs, 2018, Journal of cardiovascular pharmacology and therapeutics.

Martin/Hopkins Estimation, Friedewald and Beta-Quantification of LDL-C in Patients in FOURIER*

A. Keech, R. Giugliano, M. Sabatine, 2018 .

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes

Jennifer G. Robinson, J. Robinson, F. Raal, 2015 .

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.

Piotr Ponikowski, Andrew A. Wolff, John G. F. Cleland, 2016, Journal of the American College of Cardiology.

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

J. G. Slatter, J. Gibbs, M. Emery, 2016, Journal of clinical pharmacology.

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

G. Watts, R. Rosenson, E. Bruckert, 2014, Journal of the American College of Cardiology.

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

C. Ballantyne, E. Stein, R. Češka, 2014, The New England journal of medicine.

Evolocumab in hyperlipidemia.

E. Stein, S. Wasserman, D. Blom, 2014, The New England journal of medicine.

Clinical study of Repatha: it does not affect patients’ cognitive function and significantly reduce blood lipid and prevent coronary atherosclerosis

Carmela, R. Giugliano, M. Sabatine, 2022 .

Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism".

M. Sabatine, G. Watts, S. Wasserman, 2017, Circulation.

New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk

Jennifer G. Robinson, G. De Backer, C. Shear, 2018, European heart journal. Cardiovascular pharmacotherapy.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

R. Giugliano, M. Sabatine, N. Desai, 2012, The Lancet.

Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

R. Giugliano, M. Sabatine, N. Desai, 2012, Clinical cardiology.

Molecular Biology Applications in Cardiovascular Medicine

T. Quertermous, R. Tabibiazar, Eugene Yang, 2005 .

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

G. Watts, S. Marcovina, S. Wasserman, 2018, European heart journal.

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

A. Keech, R. Giugliano, M. Sabatine, 2017, The Lancet.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Jennifer G. Robinson, R. Giugliano, M. Sabatine, 2015, The New England journal of medicine.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Lesley Burgess, Russell Scott, Rob Scott, 2015, The Lancet.

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

G. Watts, S. Wasserman, R. Scott, 2017, Circulation.

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]

J. Jukema, W. Yeh, E. Pieterman, 2014, Journal of Lipid Research.

A Novel Interleukin-17 Receptor-like Protein Identified in Human Umbilical Vein Endothelial Cells Antagonizes Basic Fibroblast Growth Factor-induced Signaling*

M. Gerritsen, S. Wasserman, Ruey-Bing Yang, 2003, Journal of Biological Chemistry.

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.

A. Shaywitz, M. Retter, E. Stein, 2012, Journal of the American College of Cardiology.

Romosozumab in postmenopausal women with low bone mineral density

Cesar Libanati, Steven Boonen, Michael R McClung, 2014, The New England journal of medicine.

Identification of a Novel Family of Cell-surface Proteins Expressed in Human Vascular Endothelium*

S. Colman, J. Tomlinson, S. Wasserman, 2002, The Journal of Biological Chemistry.

chapter 1 – The Endothelium

S. Wasserman, J. N. Topper, 2006 .

Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know.

M. Karow, I. Foltz, S. Wasserman, 2013, Circulation.

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

P. Ponikowski, P. Poole‐Wilson, S. Anker, 2007, Journal of the American College of Cardiology.

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

H. Bays, S. Wasserman, R. Scott, 2014, Journal of the American College of Cardiology.

Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol‐Lowering Therapy

G. Watts, B. Coll, S. Marcovina, 2019, Journal of the American Heart Association.

A Novel Secreted, Cell-surface Glycoprotein Containing Multiple Epidermal Growth Factor-like Repeats and One CUB Domain Is Highly Expressed in Primary Osteoblasts and Bones*

M. Tsai, S. Wasserman, Ruey-Bing Yang, 2004, Journal of Biological Chemistry.

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.

C. Ballantyne, S. Nissen, R. Rosenson, 2016, JAMA.

The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function

B. Weinstein, F. Cao, Xiaoyan Xie, 2014, Journal of Cell Science.

Cognitive Function in a Randomized Trial of Evolocumab

A. Keech, R. Giugliano, M. Sabatine, 2017, The New England journal of medicine.

Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia

P. Armstrong, H. Krum, B. Massie, 2008, Circulation.

The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure

P. Ponikowski, D. J. Veldhuisen, S. Anker, 2009, European journal of heart failure.

Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial

S. Solomon, M. Pfeffer, R. Diaz, 2009, European journal of heart failure.

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

P. Ponikowski, S. Solomon, I. Piña, 2013, European journal of heart failure.

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

A. Keech, R. Giugliano, M. Sabatine, 2016, American heart journal.

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

S. Solomon, K. Mahaffey, T. Povsic, 2017, Cardiovascular Drugs and Therapy.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.

PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

A. Marais, S. Wasserman, G. Lambert, 2015, Pharmacology & therapeutics.

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

W. Koenig, C. Ballantyne, J. Kastelein, 2020, American journal of preventive cardiology.

Effect of Evolocumab on Coronary Plaque Composition.

W. Koenig, C. Ballantyne, J. Kastelein, 2018, Journal of the American College of Cardiology.

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

W. Koenig, C. Ballantyne, J. Kastelein, 2016, JAMA.

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).

W. Koenig, C. Ballantyne, J. Kastelein, 2016, American heart journal.

PCSK9 Inhibitors and Cardiovascular Events.

M. Sabatine, E. Stein, S. Wasserman, 2015, The New England journal of medicine.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

S. Wasserman, R. Scott, Thomas Liu, 2012, The Lancet.

Evolocumab (AMG 145) for primary hypercholesterolemia

M. Emery, S. Wasserman, G. Langslet, 2015, Expert review of cardiovascular therapy.

Psychometric Properties of a Swedish Version of the Kansas City Cardiomyopathy Questionnaire in a Chronic Heart Failure Population

J. Spertus, I. Ekman, L. Persson, 2008, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.

P. Ponikowski, K. Dickstein, A. Cohen-Solal, 2008, European heart journal.

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Abstract 2736: The Effect of Increased Hemoglobin Concentration on Clinical Outcomes in Patients With Symptomatic Heart Failure and Anemia: Results From STAMINA-HeFT

P. Armstrong, H. Krum, B. Massie, 2006 .

Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab

J. Kastelein, S. Nissen, S. Nicholls, 2021, JACC: Cardiovascular Imaging.

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

J. Gibbs, M. Emery, M. Gibbs, 2018, Clinical Pharmacokinetics.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, JAMA.

Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy

R. Rosenson, E. Stroes, L. Cho, 2014, Clinical cardiology.

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, Clinical cardiology.

Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.

S. Yamashita, A. Hirayama, T. Teramoto, 2014, Circulation journal : official journal of the Japanese Circulation Society.

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

V. Gebski, E. Stein, A. Olsson, 2012, JAMA.

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies

Jennifer G. Robinson, F. Raal, E. Stroes, 2018, Clinical cardiology.

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies

O. Descamps, N. Sattar, J. Genest, 2017, Circulation.

Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig)

F. Raal, R. Santos, D. Blom, 2016 .

CLINICAL EQUIVALENCE OF EVOLOCUMAB AMONG PATIENT SUBGROUPS IN PROFICIO: A POOLED ANALYSIS OF 3146 PATIENTS FROM PHASE 3 STUDIES

Jennifer G. Robinson, F. Raal, E. Stroes, 2015 .

LDL CHOLESTEROL REDUCTION IN ELDERLY PATIENTS WITH THE PCSK9 MONOCLONAL ANTIBODY EVOLOCUMAB (AMG 145): A POOLED ANALYSIS OF 1779 PATIENTS IN PHASE 2, 3 AND OPEN LABEL EXTENSION STUDIES

R. Rosenson, E. Stroes, N. Honarpour, 2015 .

EFFECTS OF EVOLOCUMAB (AMG 145) IN HYPERCHOLESTEROLEMIC, STATIN-TREATED, JAPANESE PATIENTS AT HIGH CARDIOVASCULAR RISK: RESULTS FROM THE PHASE III YUKAWA 2 STUDY

A. Hirayama, A. Kiyosue, N. Honarpour, 2015 .

Abstract 16196: Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9

R. Giugliano, M. Sabatine, N. Desai, 2014 .

Abstract 16865: Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)

R. Giugliano, E. Stroes, S. Wasserman, 2014 .

Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome

R. Holman, C. Ballantyne, D. Blom, 2017, Diabetes, obesity & metabolism.

EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY

A. Shaywitz, E. Stein, J. Gibbs, 2012 .

Efficacy of evolocumab (AMG 145) in patients with PCSK9 gain-of-function mutations

G. Watts, M. Harada‐Shiba, H. Makino, 2014 .

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Hong Wang, A. Keech, R. Giugliano, 2020, Stroke.

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Leveraging electronic health records for clinical research

Keith Marsolo, Sudha R. Raman, Norman Stockbridge, 2018, American heart journal.

Development and preliminary validation of a Function IndeX for Trauma (FIX-IT).

M. Bhandari, N. Yurgin, S. Wasserman, 2013, Canadian journal of surgery. Journal canadien de chirurgie.

Gene expression profile of human endothelial cells exposed to sustained fluid shear stress.

F. Spriggs, L. Komuves, Ying Zhang, 2002, Physiological genomics.

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

M. Sabatine, E. Stein, S. Wasserman, 2015 .

A COMPREHENSIVE SAFETY ANALYSIS OF 6026 PATIENTS FROM PHASE 2 AND 3 SHORT AND LONG TERM CLINICAL TRIALS WITH EVOLOCUMAB (AMG 145)

E. Stein, O. Descamps, N. Sattar, 2015 .

SCLEROSTIN NEUTRALIZING ANTIBODY ENHANCES BONE HEALING DURING DISTRACTION OSTEOGENESIS IN RATS

S. Wasserman, M. McDonald, H. Ke, 2010 .

Abstract 15743: Long-Term Reduction in Lipoprotein (a) With the PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of 3278 Patients in Phase 2, 3, and Open Label Extension Studies

R. Giugliano, M. Sabatine, F. Raal, 2014 .

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

C. Ballantyne, E. Stein, R. Češka, 2014, The New England journal of medicine.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Jennifer G. Robinson, R. Giugliano, M. Sabatine, 2015, The New England journal of medicine.

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.

A. Keech, R. Giugliano, M. Sabatine, 2019, Journal of the American College of Cardiology.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

D. Gaudet, F. Raal, F. Civeira, 2015, The Lancet.

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.

P. Ponikowski, K. Dickstein, G. Filippatos, 2016, Journal of the American College of Cardiology.

A. Shaywitz, M. Retter, E. Stein, 2012, Journal of the American College of Cardiology.

ORIGINAL RESEARCH ARTICLE Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial

R. Giugliano, M. Sabatine, M. O’Donoghue, 2019 .

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk.

A. Hirayama, A. Kiyosue, C. Kurtz, 2016, The American journal of cardiology.

Correction.

A. Keech, R. Giugliano, N. Chawla, 2019, Journal of the American College of Cardiology.

R. Rosenson, E. Stroes, L. Cho, 2014, Clinical cardiology.

Abstract 14154: Final Report of the OSLER-1 Study: Long-Term Evolocumab for the Treatment of Hypercholesterolemia

R. Giugliano, M. Sabatine, F. Raal, 2018 .

Abstract 12621: Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance

G. Watts, L. Simons, R. Weiss, 2013 .

AMG 145, a Fully Human Monoclonal Antibody Against PCSK9, Reduces LDL-C in Healthy Volunteers and Patients on Stable Doses of Statins†

A. Shaywitz, M. Retter, E. Stein, 2012 .